Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun;41(5):251-258.
doi: 10.1089/jop.2024.0112. Epub 2025 Apr 14.

Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol

Affiliations
Randomized Controlled Trial

Understanding Individual Intraocular Pressure Response to Treatment with Latanoprost and Timolol

Jeremy C Reitinger et al. J Ocul Pharmacol Ther. 2025 Jun.

Abstract

Purpose: To identify reasons for variable intraocular pressure (IOP) responses to latanoprost and timolol in healthy volunteers and to generate the control group as part of Eye Dynamics and Engineering Network. Methods: In this multicenter, randomized, crossover study (NCT01677507), both eyes of 106 healthy subjects (212 eyes) were treated with latanoprost or timolol for 7 days, with a 6-week washout between treatments. Ocular biometrics, tonometry, and aqueous humor dynamics (AHD) were assessed at baseline and day 8 of each treatment. Subjects were divided into responders and nonresponders using cutoffs of >15% or >10% IOP reduction. Treatment effects and correlations were analyzed with paired t-tests. Results: More subjects responded to latanoprost (54%) than timolol (27%) at >15% cutoff (p < 0.01). Responders had higher mean baseline IOP than nonresponders for both drugs at both cutoffs (p < 0.01). Among timolol nonresponders (n = 56), 39% responded to latanoprost in both eyes, 20% in one eye, and 41% in neither. Among latanoprost nonresponders (n = 31), 13% responded to timolol in both eyes, 13% in one eye, and 74% in neither. Latanoprost increased uveoscleral outflow, while timolol reduced aqueous flow and outflow facility. Low baseline uveoscleral outflow was associated with latanoprost response. Conclusions: Higher baseline IOP predicted better responses to both drugs. Higher baseline uveoscleral outflow predicted nonresponse to latanoprost. No AHD differences were linked to the timolol response. Timolol nonresponders were often responsive to latanoprost, but not vice versa.

Keywords: aqueous humor dynamics; glaucoma; intraocular pressure; latanoprost; timolol.

PubMed Disclaimer

References

    1. Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma. Ophthalmology 2016;123(1):129–140; doi: 10.1016/j.ophtha.2015.09.005 - DOI - PMC - PubMed
    1. Camras CB, Hedman K, US Latanoprost Study Group . Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma 2003;12(6):466–469; doi: 10.1097/00061198-200312000-00004 - DOI - PubMed
    1. DuBiner HB, Mroz M, Shapiro AM, et al. ; Brimonidine vs. Latanoprost Study Group . A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: A three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 2001;23(12):1969–1983; doi: 10.1016/S0149-2918(01)80150-8 - DOI - PubMed
    1. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol 2002;47(Suppl 1):S65–S76; doi: 10.1016/S0039-6257(02)00301-6 - DOI - PubMed
    1. Ikeda Y, Mori K, Ishibashi T, et al. Latanoprost nonresponders with open-angle glaucoma in the Japanese POPULATION. Jpn J Ophthalmol 2006;50(2):153–157; doi: 10.1007/s10384-005-0293-x - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources